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Summary and General Discussion 
Cardiovascular disease (CVD) is the main cause of mortality and morbidity worldwide. Among 
cardiovascular diseases, coronary artery and stroke are the major cause of death. About 50% 
of CVDs relate to coronary artery disease (CAD) [1-4]. CAD is the main cause of heart failure 
(HF) [5]. Acute myocardial infarction (aMI) starts after occlusion of a coronary artery, often as 
the consequence of CAD, which deprives of the downstream myocardium of oxygen causing 
apoptosis and necrosis of the cardiomyocytes. Following aMI, an inflammatory response 
develops as the initiation of the physiological wound healing mechanism. This process is 
followed by scar tissue formation. Unfortunately, this type of ‘functional’ cardiac repair is 
associated with loss of cardiac function and development of arrhythmia. Currently available 
treatments aim to limit the immediate myocardial injury and attempt to prevent additional 
damage by restoring tissue perfusion immediately after aMI [6-9]. However, the incidence of 
heart failure associated to aMI has increased over the past decade. Therefore, an alternative 
therapy is required. In the past decades, regenerative medicine became an interesting and 
promising therapeutic strategy for CVD. Regenerative medicine may facilitate cardiac function 
by modulation of the formation of scar tissue, prevention loss of cardiac cells and re-growing 
healthy cardiac tissue either in situ or in vitro. Loss of cardiomyocytes due to ischemia and 
inflammation after myocardial infarction is the main issue of cardiac function. Since the early 
2000’s, stem cell therapy was expected to be an alternative treatment for cardiovascular 
diseases. Different cell types have been used in preclinical studies, to improve vascularization 
(EPC, MSC), remodeling (MSC) and reconstruct myocardium (differentiation of 
cardiomyocytes from EPC or iPSC) [10,11]. The first MSC which has been used as a therapy for 
aMI were isolated from bone marrow. Adipose tissue-derived stem cells (ADSC) are 
mesenchymal stem cells from white fat tissue. ADSC have many common properties with 
bone marrow-derived mesenchymal stem cells (BM-MSC). The main advantage of ADSC over 
other stem cells, including BM-MSC, is their availability as well as their ease of harvesting by 
minimally invasive methods and differentiation capacity. Indeed, most clinical studies that 
assess ADSC in clinical trials to date, have employed autologous preparations derived by 
enzymatic or mechanical processing of adipose tissue to obtain ADSC [12]. ADSC have a series 
of benefits in comparison to other stem cell types, such as well-characterized, non-
controversial, clinically relevant volumes, role as regulatory cells. And most importantly, they 
are non-malignant in comparison to iPSC which have an underlying risk to form teratomas. In 
addition, intraoperative availability of ADSC is plus, however, their therapeutical secretome 
has been poorly studied to date i.e. pre-culturing might be required to prime ADSC towards 
therapeutically beneficial cells for treatment of CVD [13-18]. 
The findings of the beneficial effects of ADSC on tissue repair have been replicated by 
numerous groups with complementary experimental designs in animal and clinical studies. 
These effects sparked research on the beneficial role of ADSC in cardiovascular pathobiology, 
as well as the design of additional (pre)clinical studies directed towards treatment of ischemic 
tissues. However, the overall efficacy of stem cell therapy is hampered by limitations that 
include insufficient retention and survival of stem cells after implantation. The development 
of cell therapy as a feasible therapeutic option in the tissue repair and regenerative medicine 
such as a treatment of myocardial infarction (MI) is in part dependent on the new strategies 
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to enable viable cells to remain in the injection site and exert therapeutic benefit for 
extended periods. Several strategies have been used to improve the retention and survival of 
stem cells e.g. genetic modification, preconditioning, and pretreatment [19-22] to provide a 
surrogate extracellular matrix for administered cells to enhance cellular retention at the 
damaged tissue. In chapter 2 we assessed the effect of various cross-linking methods on the 
biological behavior of ADCS. Recombinant collagen peptides (RCP) can be produced by 
genetically modified yeast [23]. The flexibility of RCP to make various types of scaffolds make 
them suitable for tissue engineering purposes [24]. However, to make interactive 
biomaterials, functionalized surface to promote the adhesion and survival of the cells is an 
important factor. RGD (tri- amino acid sequence, arginine-glycine-aspartate) is the most 
studied adhesive peptide in the biomaterial field. However, we found that cross-linking of RCP 
based biomaterials outrivals integrin binding motives for adhesion and function of ADSC. In 
addition, we showed that the mode of cross-linking plays a crucial role and should be taken 
along. As discussed in chapter 2, biological functions of ADSC on HMDIC-High cross- linked 
biomaterials were comparable to the Gold Standard control i.e. Tissue Culture Polystyrene. 
Stem cell therapy is a promising therapeutic option to treat patients after myocardial 
infarction. However, the intramyocardial administration of large amounts of mesenchymal 
stem cells might act as a pro- arrhythmic substrate. Pro-arrhythmic effects can be due to 
electrotonic or paracrine mechanisms or the combination of both [1]. Besides, the 
therapeutic window is narrow and demands efficient expansion   of stem cells, while in 
patients these can be impaired due to effects of aging and underlying disease. The use of 
allogeneic or xenogeneic stem cells would be an alternative to autologous cells, but 
differences in the pro-arrhythmic effects of ADSC across species are unknown. Preclinical, i.e. 
animal models, for aMI model are the important role in fundamental research to understand 
the mechanisms and potential therapeutic effect of drugs or stem cells. However, the 
translation of results obtained with animal models proves difficult. These failures could be 
due to the inter-species differences that influence the translation of animal findings to 
human. 
In chapter 3 and 4 we investigated the pro-arrhythmogenic effect of ADSC across species and 
ADSC loaded MS on cardiomyocytes. Our results revealed that co-cultures of cardiomyocytes 
with ADSC alone lowered their conduction velocity (CV) and larger conduction heterogeneity 
in comparison with the control. However, in the presence of ADSC-loaded microspheres 
conduction velocity and conduction heterogeneity were not affected. Since paracrine 
signaling was expected to play a role, ADSC-CM effect was also investigated. We have shown 
that ADSC-CM also had a pro-arrhythmogenic effect on cardiomyocytes. Application of ADSC 
to a monolayer of cardiomyocytes causes heterogeneous conduction slowing and 
fractionation by both paracrine and electronic mechanisms. Interestingly, recombinant 
collagen peptides (RCP) based microspheres attenuate these effects suggesting that 
biomaterial-guided stem cell therapy may prevent potentially arrhythmogenic effects caused 
by stem cells. Yet, the other challenge is the translation of in vitro findings to the in vivo 
context. For instance, application of biomaterials is followed by an inflammatory response 
against the material known as foreign body response (FBR). An adverse course of a FBR, e.g. 
too fast degradation or too high influx of pro-inflammatory cells, may cause the material to 
fail and the desired tissue repair to be compromised. Implantation of (bio) materials always 
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induces an FBR, which may range from almost no tissue response to severe inflammation 
with accompanying tissue destruction and loss of function. The composition and course of a 
FBR against a biomaterial is virtually impossible to predict and requires in vivo assessment. In 
chapter 5 we examined the FBR against RCP MS either with or without ADSC. Production of 
recombinant collagen allows for the on-demand design of collagen, which is why we aim at 
developing Recombinant collagen peptide (RCP) MS, as an example is adjusted with 
intramolecular RGD sequences (RCP-RGD) in order to prime and stimulate integrin-mediated 
adhesion and survival of cells. Our results showed that cross-linked RCP MS supported 
adhesion and function of ADSC (chapter 2, 4 and 5). Macrophages are known as the main 
player in FBR. Our in vivo results showed macrophage infiltration was lower in ADSC loaded 
group at day 14, however at the later time point, no differences were observed. Fibrotic 
tissue formation is the hallmark of implants failure and ADSC known to have an anti-fibrotic 
effect, our findings revealed in ADSC-loaded MS at day 28, less ECM deposition was present. 
A reduced collagen deposition inside the ingrowth and surrounding tissue was observed in 
ADSC loaded MS in comparison with the bare MS. Interestingly, our findings showed no 
myofibroblasts in the implants and also no differences in vessels density between different 
experimental groups and time points were observed. In conclusion, our in vitro and in vivo 
findings showed that RCP MS are suitable for tissue engineering and regenerative medicine 
purposes. 
As mentioned above, among the diversity of CVD, occluding arteries due to atherosclerosis 
cause a high demand for replacement vessels. Unfortunately, the seemingly relatively simple 
structure of a medium-sized artery proved difficult to recreate in the lab. In chapter 6 we 
investigated the beneficial effect of differentiated ADSC toward smooth muscle cells in 
combination with the scaffold for small vessels tissue engineering. We have shown that ADSC 
with either chemical or mechanical stimulation could differentiate into functional smooth 
muscle cells. In addition, our results showed that the mechanical stimulation could be a 
replacement for chemical stimulation and that pre-differentiated ADSC keeps their new 
phenotype with higher expression of SMC markers. 
In chapter 7, we highlighted the main pathobiology of abdominal aortic aneurysm (AAA) and 
introduce ADSC as a new promising therapeutic source for small AAA. An Aneurysm refers the 
vessel wall dilation for more than 50%. Abdominal aortic aneurysm (AAA) refers to the 
dilation and weakening of all three layers of the abdominal aorta, which mostly occur 
infrarenally. In general, pathological features of AAA include inflammation, degradation of the 
extracellular matrix (ECM), and smooth muscle cell apoptosis. The main pathophysiology of 
AAA development is still unknown. Besides available treatment modalities for large AAA, 
which associate with a high mortality risk, an effective, alternative, and safer treatments are 
required, preferably already at an early stage of AAA. For the last decades, tissue engineering 
and regenerative medicine showed promising potential therapeutic effects for various 
(cardiovascular) diseases, including AAA. Adipose tissue-derived stromal cells (ADSC) are a 
candidate source of stem cells for regenerative medicine. In chapter 8, we assessed the 
periadventitially applied ADSC-loaded patches of the recombinant collagen-based peptide 
(RCP) therapeutical potential in AAA model. Our results showed ADSC-loaded patches delay 
AAA development and progression. We have shown that local periadventitial delivery of ADSC 
using RCP-based patches suppresses the progression of AAA, as well as reduces degradation 
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of elastin and apoptosis of medial smooth muscle cells. Local delivery of ADSC in combination 
with biomaterial as an external scaffold is attractive to develop as clinical modality as a novel 
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